These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38482675)

  • 1. TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma.
    Brunelli M; Gobbo S; Malpeli G; Sirgiovanni G; Caserta C; Munari E; Francesconi S; Caliò A; Martignoni G; Cimadamore A; Veccia A; Antonelli A; Tucci M; Pierconti F; Hattab IM; Eccher A; Ascani S; Milella M; Buffoni L; Cheng L; Bracarda S
    Pathologica; 2024 Feb; 116(1):55-61. PubMed ID: 38482675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
    Bahlinger V; Branz A; Strissel PL; Strick R; Lange F; Geppert CI; Klümper N; Hölzel M; Wach S; Taubert H; Sikic D; Wullich B; Angeloni M; Ferrazzi F; Diehl L; Kovalenko M; Elboudwarej E; Jürgensmeier JM; Hartmann A; Eckstein M
    Histopathology; 2024 Apr; 84(5):863-876. PubMed ID: 38196202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
    Ghali F; Vakar-Lopez F; Roudier MP; Garcia J; Arora S; Cheng HH; Schweizer MT; Haffner MC; Lee JK; Yu EY; Grivas P; Montgomery B; Hsieh AC; Wright JL; Lam HM
    Clin Genitourin Cancer; 2023 Dec; 21(6):669-678. PubMed ID: 37344281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.
    Martini DJ; Case KB; Gratz D; Pellegrini K; Beagle E; Schneider T; Dababneh M; Nazha B; Brown JT; Joshi SS; Narayan VM; Ogan K; Master VA; Carthon BC; Kucuk O; Harik LR; Bilen MA
    Cancer; 2024 Nov; 130(21):3658-3670. PubMed ID: 38959291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of fluorescence in situ hybridization for detection of bladder urothelial carcinoma in routine clinical practice.
    Kwak KW; Kim SH; Lee HM
    J Korean Med Sci; 2009 Dec; 24(6):1139-44. PubMed ID: 19949672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of fluorescence in situ hybridization for diagnosis and surveillance of bladder urothelial carcinoma.
    Huang JW; Mu JG; Li YW; Gan XG; Song LJ; Gu BJ; Fu Q; Xu YM; An RH
    Urol J; 2014 Nov; 11(6):1974-9. PubMed ID: 25433477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.
    Hoffman-Censits JH; Lombardo KA; Parimi V; Kamanda S; Choi W; Hahn NM; McConkey DJ; McGuire BM; Bivalacqua TJ; Kates M; Matoso A
    Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):619-625. PubMed ID: 33901032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.
    Fatima N; Osunkoya AO
    Hum Pathol; 2014 Aug; 45(8):1625-9. PubMed ID: 24824028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
    Brunelli M; Tafuri A; Cima L; Cerruto MA; Milella M; Zivi A; Buti S; Bersanelli M; Fornarini G; Vellone VG; Rebuzzi SE; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Alongi F; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Antonelli A
    J Clin Pathol; 2022 Jan; 75(1):39-44. PubMed ID: 33144356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
    Wong JL; Rosenberg JE
    Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma.
    Toda S; Sato S; Saito N; Sekihara K; Matsui A; Murayama D; Nakayama H; Suganuma N; Okubo Y; Hayashi H; Iwasaki H; Miyagi Y; Hoshino D
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer.
    Wucherpfennig S; Rose M; Maurer A; Cassataro MA; Seillier L; Morsch R; Hammad E; Baldia PH; Ecke TH; Vögeli TA; Knüchel R; Gaisa NT
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients.
    Liu J; Cai M; Chen J; Liao Y; Mai S; Li Y; Huang X; Liu Y; Zhang J; Kung H; Zeng Y; Zhou F; Xie D
    Eur J Cancer; 2014 Mar; 50(4):840-51. PubMed ID: 24388773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
    Petros FG; Choi W; Qi Y; Moss T; Li R; Su X; Guo CC; Czerniak B; Dinney C; McConkey DJ; Matin SF
    J Urol; 2021 Sep; 206(3):548-557. PubMed ID: 33881933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLKL and other necroptosis-related genes promote the tumor immune cell infiltration, guiding for the administration of immunotherapy in bladder urothelial carcinoma.
    Zhong B; Wang Y; Liao Y; Liang J; Wang K; Zhou D; Zhao Y; Jiang N
    Apoptosis; 2023 Jun; 28(5-6):892-911. PubMed ID: 37000317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma.
    Tekin B; Cheville JC; Herrera Hernandez L; Negron V; Smith CY; Jenkins SM; Dasari S; Enninga EAL; Norgan AP; Menon S; Cubilla AL; Whaley RD; Jimenez RE; Thompson RH; Leibovich BC; Karnes RJ; Boorjian SA; Pagliaro LC; Erickson LA; Guo R; Gupta S
    Hum Pathol; 2023 Dec; 142():42-50. PubMed ID: 37977513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.
    Abbas M; Heitplatz B; Bernemann C; Boegemann M; Trautmann M; Schrader AJ; Wardelmann E; Schlack K
    Oncol Lett; 2023 Dec; 26(6):527. PubMed ID: 38020299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
    Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
    Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of urine cyclic RNA-0071196 for bladder urothelial carcinoma.
    Yang Y; Li J; Yao W; Zou G; Ye X; Mo Q
    BMC Urol; 2024 Apr; 24(1):88. PubMed ID: 38627689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.